Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from enGene Holdings ( (ENGN) ).
On July 7, 2025, Jasper Bos resigned from enGene’s Board of Directors, and Philip Astley-Sparke was appointed to fill the vacancy. Subsequently, the Board expanded to nine members with the addition of William Grossman and Michael Heffernan. These appointments, along with management promotions of Matthew Boyd, Jill Buck, and Katherine Chan, aim to support enGene’s strategic transition towards the commercialization of its lead therapy, detalimogene. The new directors bring extensive experience in gene therapy, oncology, and product launches, which is expected to enhance enGene’s clinical and regulatory operations as the company prepares for planned regulatory filings and commercialization of detalimogene.
The most recent analyst rating on (ENGN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for mucosal tissues and other organs. The company’s lead program is detalimogene voraplasmid, a non-viral gene-based immunotherapy for Non-Muscle Invasive Bladder Cancer (NMIBC), particularly targeting patients with Bacillus Calmette-Guérin (BCG)-unresponsive carcinoma in situ (CIS).
Average Trading Volume: 82,881
Technical Sentiment Signal: Sell
Current Market Cap: $194.7M
See more data about ENGN stock on TipRanks’ Stock Analysis page.